GpCRC Pediatric Gastroparesis Registry 2

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age8-25
SponsorJohns Hopkins Bloomberg School of Public Health

About this trial

The objective of the Pediatric Gastroparesis Registry 2 is to create a national prospective registry of children, adolescents, and young adults with gastroparesis and gastroparesis-like syndrome (symptoms of gastroparesis but normal gastric emptying).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Provision of signed and dated informed consent form and assent, as age appropriate.

Stated willingness to comply with all study procedures and availability for the duration of the study

8 to 25 years of age at the time of enrollment

Delayed gastric emptying-defined as an abnormal 2-hour (>60% retention) and/or 4- hour (>10% retention) result based on a 4-hour scintigraphic gastric emptying study

Disqualifiers

Inability to comply with or complete the scintigraphic gastric emptying test (including allergy to eggs)

Pregnancy

Autism spectrum disorder, significant developmental delay, psychosis (because of inability to complete questionnaires)

Use of narcotic analgesics greater than three days per week.

Trial population

The study population will be 216 participants aged 8-25 years of age with symptoms of Gp located in the United States.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

216 Participants
are grouped into 2 trial groups
Group A: Ages 8-25 with delayed gastric emptying
Group B: Ages 8-25 with normal gastric emptying

Trial outcomes

Primary outcomes

1

Change in mean symptom severity of gastrointestinal symptoms using the change in total score from the Pediatric Quality of Life Inventory (PedsQL) Gastrointestinal Symptoms Scales™

The PedsQL™ GI Symptoms Scales questionnaire has 65 response items covering 10 dimensions, with each item offered as a better-to-worse 5-point Likert scale choice: 0=never, 1=almost never, 2=sometimes, 3=often, 4=almost always. The item responses are transformed to a worse-to-better order and rescaled to 0-100: 0=almost always, 25= often, 50=sometimes, 75=almost never, 100= never, with higher scores indicating better health-related quality of life (HRQOL) and fewer problems or symptoms.he per-participant PedsQL™ GI Symptoms Scales total score is the sum of the 65 transformed and rescaled item responses. The primary outcome measure is the arithmetic mean of the 65 transformed item responses and is repeated at baseline and 48 weeks for each participant.

Time frame
Baseline, 48 weeks

Secondary outcomes

1

Presence or absence of Carnett's sign as assessed by abdominal examination

Presence or absence Carnett's sign for abdominal wall pain at baseline. Carnett's sign is a finding on clinical examination in which (acute) abdominal pain remains unchanged or increases when the muscles of the abdominal wall are tensed. As part of the abdominal examination, the patient is asked to lift the head and shoulders from the examination table to tense the abdominal muscles. An alternative is to ask the patient to raise both legs with straight knees. A positive test indicates the increased likelihood that the abdominal wall and not the abdominal cavity is the source of the pain (for example, due to rectus sheath hematoma instead of appendicitis). A negative Carnett's sign is said to occur when the abdominal pain decreases when the patient is asked to lift the head; this points to an intra-abdominal cause of the pain.

Time frame
Baseline
2

Change in volume (mL) of liquid consumed as assessed by the Water Load Satiety Test

Change from baseline to 48 weeks in amount of liquid (mL) consumed during the Water Load Satiety Test (WLST) Lower volumes are signs of impaired accommodation.

Time frame
Baseline, 48 weeks
3

Change in Pain Catastrophizing Scale scores (PCS)

The outcome is assessed using change in the total score at 48-weeks minus the baseline score. A negative change indicates reduced pain catastrophizing. PCS total score is computed by summing responses to all 13 items. PCS total scores range from 0 - 52.

Time frame
Baseline, 48 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Johns Hopkins Bloomberg School of Public Health

Lead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator

Texas Tech University Health Sciences Center, El Paso

Collaborator

Baylor College of Medicine

Collaborator

Massachusetts General Hospital

Collaborator

Children's Wisconsin

Collaborator

Boston Children's Hospital

Collaborator

Nationwide Children's Hospital

Collaborator